Am19 Logo 300X300
SAN FRANCISCO - April 1, 2019 - Syapse, the leader in powering precision medicine through a global health system network, today announced the presentation of data validating the effectiveness of its real-world data platform in reliably and automatically harmonizing molecular testing results for robust clinical analysis across thousands of oncology patients. These data were presented at the American Association for Cancer Research (AACR) 2019 Annual Meeting held March 29-April 3 in Atlanta, GA.
Syapse has built a scalable system using a novel hybrid ontology-graph structure to automatically harmonize and integrate omics data into a real-world data platform to power precision oncology. Syapse integrates a broad range of tests that use many types of assays, including single-marker tests with IHC, PCR, and FISH, as well as next-generation sequencing-based gene panel tests for solid tumors using tissue and liquid biopsies.
“Rapid adoption of molecular testing has been one of the most exciting areas of innovation in cancer care in the last decade, but the lack of standardization combined with the proliferation of testing approaches, laboratories, panel sizes, and an ever increasing list of clinically actionable markers, has introduced the challenge of harmonizing patient biomarker results for analysis in an automated method at scale,” said Jonathan Hirsch, Founder and President of Syapse. “Syapse has demonstrated that we can successfully solve the variance found in the representation of clinically actionable biomarkers across laboratories through an automated real-world data platform approach. This is critically important to stakeholders including cancer care providers, health systems, life sciences, regulators, and payers, all of whom are seeking to understand the clinical utility of precision medicine at scale using real-world data.”
In this poster, Syapse discussed how it assessed and normalized the variability in representation of the same markers across laboratories for three well-known and clinically actionable biomarkers: EGFR Exon 19 Deletions, PD-L1 expression, and BRAF V600E. In this analysis, Syapse found that EGFR Exon 19 Deletions, which impact treatment decisions for patients with metastatic non-small cell lung cancer, had 43 distinct labelings in real-world data, with 12 of those 43 used by two or more testing labs. One testing lab used 16 distinct labels over 4 years. Syapse was able to automatically harmonize all of these labels into one single representation, making it easy to analyze cohorts of patients who all share that biomarker.
Syapse currently has integration agreements with more than 10 of the leading commercial and hospital-based molecular testing laboratories. Syapse works with each lab to understand their testing methods, ingest and map their data using structured industry standards, and ensure that their tests meet requirements for the Syapse data interchange. These data are used to power precision medicine solutions including clinical trials matching and outcomes research.
These data were presented at AACR today in a poster titled: “A hybrid ontology and graph system enabling precision oncology applications through real-time incorporation of omics biomarkers into a scalable real-world data platform.” The abstract can be found on the AACR website at: www.abstractsonline.com/pp8/#!/6812/presentation/6116.
About SyapseSyapse is on a mission to deliver the best care for every cancer patient through precision medicine. Our insights platform, data sharing network, and industry partnerships enable healthcare providers to bring precision cancer care to every patient who needs it. By bringing together leading healthcare innovators into a unified ecosystem, we have built one of the world’s largest learning health networks of provider-driven precision medicine data. In collaboration with our customers — including Advocate Aurora Health, CommonSpirit Health, Henry Ford Health System, Providence St. Joseph Health, and Seoul National University Hospital — we are working toward a future in which all cancer patients have access to the best personalized care, regardless of location or income.